Breyanzi (lisocabtagene maraleucel)

P2, N=9, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=20 --> 9

P2, N=50, Active, not recruiting, M.D. Anderson Cancer Center | Suspended --> Active, not recruiting

P2, N=50, Suspended, M.D. Anderson Cancer Center | N=10 --> 50

P2, N=10, Suspended, M.D. Anderson Cancer Center | Recruiting --> Suspended

Axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) are standard-of-care second-line therapies for relapsed or refractory large B-cell lymphomas, yet clinical and immunological predictors of durable benefit remain poorly defined. Greater CART expansion, enrichment for naïve CD8+ CAR+ T-cells, and lower PD1 expression at day 7 post-infusion are associated with response. Thus, these findings highlight the efficacy of second-line CART and identify disease and immune-related predictors of long-term response.

We conducted a multicenter retrospective study using the French DESCAR-T registry, including patients with LBCL who relapsed after 2L CAR T-cell therapy with axicabtagene ciloleucel or lisocabtagene maraleucel. This study represents the first real-world analysis of outcomes after relapse following 2L CAR T-cell therapy. Despite the more frequent incorporation of BsAbs into the therapeutic landscape, overall prognosis and treatment efficacy remain dismal, highlighting the urgent need for innovative therapeutic strategies and dedicated prospective trials in this emerging double-refractory population.

P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting

P2, N=10, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

Liso-cel achieved deeper, more durable molecular clearance by ctDNA, consistent with superior EFS and PFS versus ASCT for second-line LBCL treatment. ctDNA-MRD provided prognostic value beyond PET, supporting its role as a complementary biomarker for treatment response and relapse prediction.

P4, N=75, Henan Cancer Hospital; Henan Cancer Hospital

These findings highlight the importance of early leukapheresis, ideally before intensive treatments, to optimize T-cell yield, product quality, and therapeutic efficacy.

P2, N=20, Not yet recruiting, Fred Hutchinson Cancer Center | Initiation date: Apr 2026 --> Jul 2026